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were adapted respectively to screen independent risk factors of SMM, and a logistic 
model was set to predict the SMM by STATA 12.0. The areas under receiver operator 
characteristic (ROC) curve and agreement rate were used to evaluate the predic-
tion model. Results: Three kinds of unexpected surgeries, transfusion, hyster-
ectomy, ICU care, Multiple Organ Dysfunction Syndrome (MODS) were chosen as 
the outcomes of SMM by literature review and expert consensus. The rate of SMM 
was 2.30% in 33993 deliveries. All specified and substantially significant risk fac-
tors were divided in four aspects. Social characteristics included the hometown 
location of pregnant women. Pre-delivery characteristics were gestational weeks, 
multiparity, abnormal pregnancy history, PPH history and smoking. The coexisted 
diseases and complications of pregnancy were gestational hypertension, preec-
lampsia and eclampsia, other gestational hypertension diseases, placenta previa, 
placenta increta, hematological disease, cardiac disease and gynecological diseases. 
The delivery characteristics contained styles of onset labor, midwifery, episiotomy, 
macrosomia, fetal death, premature rupture of membrane, uterotonic treatment. 
The areas under ROC curve and agreement rate were 0.87 and 98.05% respec-
tively. ConClusions: SMM can reflect the severe degree of maternal outcomes 
indirectly, but also illustrate potential maternal health in a country or area by pro-
viding information to influence the delivery of health services and health policy. 
Our model specified dozens of risk factors and had considerably higher value of 
ROC area and agreement rate. We will perform the prospective research to predict 
and prevent the SMM in future.
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AbstRACt obJeCtiVes: The present study is a meta-analysis of clinical studies 
conducted to evaluate the efficacy of oximes in the treatment of organophospho-
rus (OP) intoxicated patients. Methods: PubMed, Scopus, Google Scholar, and 
clinicaltials.gov were searched for studies investigated the effects of oximes in the 
treatment of OP poisoning. Mortality, intermediate syndrome, intensive care unit 
(ICU) admission rate, and intubation rate were the key outcomes of interest. Data 
were searched in the time period of 1966 through December 2013. Results: Ten 
studies (nine clinical trials and one historical cohort) that met our criteria were 
included in the analysis. Pooling of data showed that relative risk (RR) of need for 
intubation in OP poisoning for eight included trials comparing oximes to placebo 
was 1.27 with 95% CI= 0.73 to 2.23 (P= 0.4). RR of only one observational study 
was 1.57 (95% CI= 0.79 to 3.2, P> 0.05). The summary of RR for mortality rate in 9 
studies was 0.38 (95% CI= 0.65 to 2.97, P= 0.41) and for one observational study 
was 1.33 (95% CI= 0.54 to 3.29, P> 0.05). The RR for ICU admission rate in OP poi-
soning for three trials comparing oximes to placebo was2.12 with 95% CI= 0.89 to 
5.03 (P= 0.09). For only one observational study, RR was 0.81 (95% CI= 0.49 to 1.25, 
P> 0.05). For intermediate syndrome, while the RR of only trial comparing oximes 
with placebo was 1.89 (95% CI= 1.27 to 2.91, P< 0.05) while for only one observa-
tional study, it was 1.43 (95% CI= 0.7 to 2.96, P> 0.05). ConClusions: According 
to these data, oximes beneficence in OP poisoning is unclear and if administered, 
great caution must be exercised because of increase in ICU admission rate and 
incidence of intermediate syndrome. KeywoRds: Organophosphorus, oxime, 
poisoning, meta-analysis.
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obJeCtiVes: Vaginal atrophy is a silent epidemic that affects up to 50%-60% of 
postmenopausal women. Local,low-dose estrogen preparations are considered 
first-line pharmacologic treatment. For women concerned about hormone use 
a number of over-the-counter (OTC) vaginal moisturizer and lubricant products 
are considered first-line nonhormonal treatments. It has been reported that vita-
min E vaginal gel improved the symptoms of volvovaginal atrophy However, oral 
vitamin E has never been well tested in a randomized clinical trial for efficacy 
against vaginal atrophy. Therefore the objective of this study is to assess the 
effect of vitamin E on the vaginal maturation index (VMI) of post menopausal 
women. Methods: Participants in this placebo-controlled randomized cross over 
trial were 60 menopausal women who 4-12 months passed from their menopause. 
After randomization the women were given medication blister pack cards that 
contained an 8-week supply of study medication (400IU of vitamin E or placebo 
daily). Following 1-week no treatment , baseline period, the first group received 
one vitamin E soft gel daily (400IU dl-Alpha-tocopheryl acetate) while the second 
group received placebo for four weeks. In order to eliminate the carry over effect 
of cross over trial, one week washout was considered. Then the medication was 
reversed for each group and the study was continuing for another four weeks.
Vaginal maturation index of the women before any intervention and after the 
first and second stage of treatment was evaluated. Results: The study groups 
were homogeneous regarding age, BMI, time since menopause, educational and 
job status. No statistically significant differences were observed in the percent-
age of superficial, intermediate and parabasal cells within the groups at baseline 
and after the first and second stage of treatment. ConClusions: Based on our 
trial treatment with vitamin E for 4 weeks has no effect on the maturation of the 
vaginal epithelium in postmenopausal women.
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domestic one, which also denoted COBAS test to be a less costly and more effec-
tive / dominant measure. In addition, sensitivity analysis showed the result was 
not sensitive to main indicators, including test price, week-4 and week-12 treat-
ment response rate, week-4 and week-12 false negative rate of domestic test, SVR 
rate of 24-week treatment for cEVR, and proportion of non-EVR in RNA positive in 
12th week. ConClusions: Compared with domestic HCV RNA test, for the short 
term treatment course, COBAS test can identify RVR & EVR more accurately, make 
more appropriate decisions of course period and have more patients achieve SVR. 
And in long term perspective, COBAS test plus appropriate course of treatment can 
prolong patient’s life year, improve patient’s life quality as well as decrease total 
medical expense due to less disease progress.
gasTroInTesTInal dIsorders – Health care use & Policy studies
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obJeCtiVes: Inappropriate utilization of proton pump inhibitors (PPI) and H2-
receptor antagonists (H2RA) in inpatients is prevalent, but poorly defined. We 
undertook a rigorous national audit to allow the standardization of grading system 
for appropriate use. Methods: Medical and demographic data were collected for all 
in-patients receiving a PPI or H2RA.Regimens reviewed included intravenous bolus 
PPI or H2RA (IVb), intravenous high dose continuous infusion PPI or H2RA (IVci = 
bolus followed by ci), and oral PPI or H2RA (PO); and were categorized as Endorsed 
or Not Endorsed [N-E]. Multivariate modeling was performed to assess predictors 
of E and N-E use. Results: Over 6 months, 1720 patients (age: 64.0±16.7 y, 43% 
women) receiving 2890 drug regimens were included from 21 Canadian institutions. 
28% were taking a PPI and 7% an H2RA before admission. 95% of in-hospital drug 
regimens used a PPI and only 5% a H2RA. 32% of drug regimens were endorsed. 
Proportions for E and N-E uses were 28.0 [25.5,30.7] and 72.0 [69.3-74.5], 18.2 [15.1-
21.7] and 81.8 [78.3-84.9], and 42.9 [40.0, 45.8] and 57.1 [52.2, 60.0] for IVb, IVci, and 
PO respectively. The most common indication was upper GI bleeding (70% of IVci, 
79% N-E; 18% of IVb, 69% N-E; 25% of PO regimens, 77% N-E). Stress ulcer prophylaxis 
was the prescribing indication in 8% of IVb (94% N-E), and 6% of oral (88% N-E). 
Independent predictors of E were suspicion of UGIB (for IVci and PO regimens), time 
of drug administration (for IVci and IVb), and sex (for IVci). ConClusions: Existing 
consensus recommendations provided no guidance as to appropriateness of use in 
up to 40% of regimens. Endorsed use was noted in only 28% of IVb, 18% of IVci, and 
43% of PO regimens. These data will help guide future guideline recommendations 
to optimize in-hospital prescribing of acid suppressants.
IndIvIdual’s HealTH – clinical outcomes studies
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obJeCtiVes: Polypharmacy has been associated with functional decline and 
adverse outcomes in vulnerable population and with an increased risk of Adverse 
Drug Events (ADE), particularly in fragile patients such as the elderly with complex 
medical conditions.Aim of this observational study was to describe and evalu-
ate ADE in patients with polypharmacy by a digital health service that prevents 
Drug-Drug Interactions (DDI) using the social security number (SSN). Methods: 
A cohort of 369 patients was identified through a closed loop, fully automated 
system that records and updates all the drugs taken during therapy cycle/s by spe-
cifically designed software interfaces loaded on Information and Communication 
Technology programs of the network.The tool was designed to support General 
Physicians in clinical decisions, providing them information about prescribed 
drugs/over the counter (OTC)/herbs, detailing dosage, comorbidity, number of 
packages and pills per package, prescription/purchase date. Results: About 30% 
of patients shown 1 comorbidity and 11.8% 2 or more. Cardiovascular diseases 
(22.7%) represented the most frequent comorbidity, followed by musculoskeletal 
pathology (13.6%), diabetes (8.6%), cancer (5.1%), and depression (4.8%).The Charlson 
Comorbidity Index was 0 in 65.2%, 1 in 25.7%, 2 in 7.0% and 3 to 4 in 2.1%. A total of 
67 patients (mean age 72 years; 52.2% women) had at least 1 DDI. About 50% (N = 
33) had up to 2 DDIs, 25% from 3 to 7 DDIs and 25% ≥ 8 (from 9–74 DDIs per person). 
A total of 501 DDIs were identified: the severity was low in 35.5%, moderate in 
59.7% and high in 4.8%. The top 10 drugs involved in DDI were: acetylsalicylic acid 
(ASA), hydrochlorothiazide, ibuprofen, diclofenac, digoxin, nebivolol, pantoprazole, 
ramipril, furosemide and nimesulide. ConClusions: ICT technologies are useful 
to timely identify DDIs of clinical relevance and the drugs most frequently involved.
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modelIng To PredIcT severe maTernal morbIdITy based on 33993 
delIverIes of regIsTered sTudy In cHIna
Tan J.1, Chen M.2, Li Y.1, Liu X.2, Yu C.1, Sun X.1
1West China Hospital, Sichuan University, Chengdu, China, 2West China Women’s and Children’s 
Hospital, Sichuan University, Chengdu, China
obJeCtiVes: To set a model to predict the Severe Maternal Morbidity (SMM) 
and specify the risk factors based on a registered study in Sichuan province, 
China. Methods: Overall 33993 deliveries of 8 hospitals in Sichuan province of 
China were consecutively collected between January 1, 2009, and December 31, 
2010 in our database. The forward and backward stepwise regression methods 
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IndIvIdual’s HealTH – cost studies
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usIng Hormonal conTracePTIon reduce unInTended Pregnancy In 
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obJeCtiVes: The potential high-unintended pregnancy rates have resulted in 
great productivity loss in China. Several contraceptive methods have been intro-
duced by both the providers and the woman themselves to reduce the unintended 
pregnancy rates.A cost-benefit analysis on various hormonal contraceptive meth-
ods was performed in order to provide references for contraception selection in 
China. Methods: A decision-tree model was used to compare contraception costs 
and effects among different contraceptive methods. All women were classified into 
three contraception profiles (continuation, discontinuation and switch, discontinu-
ation and drop-out).Outcomes included no pregnancy, pregnancy with no birth and 
birth. All the probabilities, medical and medication data in this model were derived 
from the literature and interviews. Results: A comparison of total estimated yearly 
and cumulative costs indicated that contraceptive implants, transdermal contracep-
tive, extended-cycle OC, vaginal ring, and IUD were less costly, less than $281733.7 in 
a three-year study period. While transdermal contraceptive, extended-cycle OC and 
vaginal ring were not available in the Chinese market, contraceptive implants and 
IUD were the only two choices in China with lowest cumulative costs. The further 
cost-benefit analysis also demonstrated contraceptive implants as good value for 
money. Using contraceptive implants were proved to have the lowest cost of preg-
nancy from failure of $839.9, with a total cost of $26814.9, and a benefit-cost ratio of 
2.2, far over 1.0. Sensitivity analysis by tornado diagrams showed that cost of preg-
nancies, age and proportion of discontinuation and switch might have the greatest 
impact on the costs and failure risks of contraceptive implants. ConClusions: In 
order to reduce the unintended pregnancy rates, the implementation of hormonal 
contraception may lead to a benefit in terms of both costs and effects. And among 
all the hormonal contraception in the Chinese market, contraceptive implants tend 
to generate greater economic benefits. Note:1US dollar= 6.46 Chinese yuan.
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obJeCtiVes: China is a big country with a large population. Reproductive health 
education is not sufficient for women of childbearing age, which leads to high 
unintended pregnancy (UP) rate. These represent a significant cost to the health care 
system. This study analyzes the epidemiology and productivity loss of unintended 
pregnancy in China. Methods: The study reviewed published scientific articles and 
policy documents related to unintended pregnancy in China. We retrieved literature 
from Wanfang and PubMed databases, and searched policy documents in websites 
of National Bureau of Statistics and National Center for Women and Children’s 
health, China CDC. Results: Almost 10% of fertile women have UP in China each 
year. There are four different results of UP, including miscarriage, elective abortion, 
ectopic pregnancy and delivery. There are two methods of elective abortion, includ-
ing operation abortion and drug abortion. The costs of operation and drug abortion 
are about US $131.58 and $100.62 in early pregnancy respectively, and $154.80 and 
$464.40 in the second trimester respectively. Drug abortion costs are much more in 
the second trimester because of complications. The incidence of ectopic pregnancy 
is about 4.4%, and there are three therapeutic methods. The costs of laparoscopic 
operation and open abdominal surgery are more than drug conservative treatment. 
The costs are between $309.60 and $1393.19. Delivery has three possibilities. Vaginal 
delivery accounted for 52.6%, and cesarean section accounted for 46.2%. The inci-
dence of premature birth is about 6.36%. Vaginal delivery and cesarean section will 
cost about $387.00 and $619.20 respectively. The costs of premature birth range from 
$928.80 to $1547.99, and the costs will be increased with high likelihood of neonatal 
weight. ConClusions: UP poses a heavy economic burden in China, but the eco-
nomic burden could be reduced if fertile women receive more reproductive health 
education, get appropriate treatment and have periodical prenatal examination.
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obJeCtiVes: Rotavirus infection was reported as the major cause of severe diar-
rhea in children under 5-years-old in Indonesia. A low cost rotavirus vaccine to 
protect infants from birth has been developed for developing countries, such as 
Indonesia. This study aims to update our initial analysis on the cost-effectiveness 
of rotavirus vaccination in Indonesia, taking a birth-dose vaccination strategy 
explicitly into account. Methods: An age-structured cohort model was developed 
for the 2013 Indonesia birth cohort. Applying different rotavirus vaccine efficacies 
for formula-fed and breastfed infants, we compared two vaccination strategies: 
(i) three-dose schedule at 2, 3 and 4 months of age, and (ii) three-dose schedule 
at 0, 1, and 2 months of age. We applied a 5-year-time-horizon with 1 monthly 
analytical cycles for children less than 1 year of age and annually thereafter. 
Also, we used Monte Carlo simulations to examine the economic acceptability 
and affordability of the rotavirus vaccination. Results: Rotavirus vaccination 
would reduce rotavirus-diarrhea cases in children under 5-years-old by 475,806 
and 489,259 cases for the first and second strategies, respectively. Considering 
amarket price of US$ 5 per dose, the Indonesian government would require budg-
ets of US$ 65.0 million and US$ 65.3 million for the first and second strategies, 
respectively.The incremental cost-effectiveness ratios wereUS$ 150 and US$ 146for 
obJeCtiVes: To assess and compare the efficacy of atropine and atropine with 
glycopyrrolate combination in organophosphate poisoning. Methods: A retro-
spective study was conducted in a tertiary care teaching hospital of South India. 
Data was collected retrospectively from medical record section from 2012 to 2013 
in a suitable designed case record form. Data was analysed by using SPSS 20.0 with 
chi-square and one way anova. Results: Total of 199 cases of organophosphate 
poisoning was documented out of which 135(67.8%) were males and 64(32.2%) 
were females. The average age in this group of patients was found to be 34.22 + 
14.26. The average pre-hospitalization period was 1.58 + 2.07 days. Among them 
majority of the cases were suicidal (94.5%). A total of 159 patients received only 
atropine as treatment with an average hospital stay of 12.66 (SD= 11.88) days and 
a mean of 8.71(SD= 10.03) days duration in ICU. Whereas the other 40 patients 
received both atropine and glycopyrrolate as treatment with an average stay of 
15.68 (SD= 12.76) days and a mean of 12.12 (SD= 10.40) days duration in ICU. 
Amongst the 159 patients who received only atropine 40.9% received ventilation 
and for the other 40 who received atropine and gylcopyrrolate only 60% received 
ventilation. Out of the 159 patients who received only atropine 7.6% underwent 
tracheostomy and 25.8% were found to have intermediate syndrome, whereas 
for patients who received both atropine and glycopyrrolate 15.4% underwent tra-
cheostomy and 35% were found to have intermediate syndrome. ConClusions: 
Efficacy of two regimens reveals that atropine was found to be more effective 
when given alone when compared with atropine and glycopyrrolate combination 
in OP poisoning.
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obJeCtiVes: To assess the effectiveness of combined biochemical and ultrasound 
screening for chromosomal abnormalities in the first trimester of pregnancy on 
reducing the rate of invasive genetic procedures in a city based population on 
Hungary. Methods: Previously women aged 35 years or more had access to cho-
rionic villus sampling (CVS) or amniocentesis (AC). A private prenatal diagnostic 
center offered a population based screening protocol irrespective of maternal age. 
Invasive testing was performed for women having a combined risk for fetal ane-
uploidy> 1:250. Total number of 4611 singleton and twin pregnancies in the ges-
tational age of 11+0 and 13+6 weeks were enrolled between November 2010 and 
August 2013. Maternal serum level of pregnancy associated protein-A (PAPP-A) and 
free-beta human chorionic gonadotropin (free β -hCG) were determined by KRYPTOR 
(Brahms-Thermofisher Gmbh, Germany). Results: The screening rate in this city 
based population was 60%. 277 (6,3%) women had a positive first trimester screen-
ing result. There were 16 fetuses with Down’s syndrome and 14 fetuses with other 
chormosomal abnormalities diagnosed. The sensitivity and specificity were 100% 
and 95%, the false positive rate was 4,5% and the false negative rate was 0%. The 
positive predictive value of the test was 11%, the negative predictive value was 100%. 
The number of pregnancies in which an invasive test was performed decreased 
from 518 in 2005 to 295 in 2013, or by 44%. The proportion of women aged less than 
35 years increased, while the rate of women over 35 decreased in this invasive 
group. ConClusions: It is possible to change the pattern of invasive prenatal 
procedures and reduce the proportion of women having CVS or amnio. Efficient 
information is needed to increase the screening rate, especially in a self-financed 
system, where the public health insurance does not cover this type of nationwide 
screening.
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obJeCtiVes: Disability-adjusted Life-years (DALYs) and Quality-adjusted Life-
years (QALYs) are two measurements commonly used in health care evaluations; 
however the specific disease areas where they are most applicable are not fully 
defined. The objective of this study was to review the use of DALYs and QALYs in 
trials taking place in China and Thailand and review the relationship with disease 
burden. Methods: PubMed was searched for studies published after 01/01/2004 
reporting DALYs and QALYs for communicable and non-communicable diseases 
in China and Thailand. Data on disease burden were obtained from the World 
Health Organisation’s (WHO) ‘Mortality and Burden of Disease Estimates for WHO 
Member States in 2004’ database. Results: 117 studies were included for China; 
79 reported QALYs and 38 reported DALYs. 34 studies were included for Thailand 
(QALYs: 28; DALYs: 6). Of trials reporting QALYs, 74.7% of Chinese and 78.6% of 
Thai trials focussed on non-communicable disease; the most commonly investi-
gated disease was cancer. Of trials reporting DALYs, 44.7% of Chinese and 16.7% 
of Thai trials focussed on non-communicable diseases. In terms of the disease 
burden, communicable/non-communicable diseases account for 24.6%/75.4% and 
33.7%/66.3% of the burden in China and Thailand respectively. Leading causes of 
disease burden were cerebrovascular disease (7.7%) and HIV (12.0%) in China and 
Thailand respectively. ConClusions: A dual burden of disease was observed in 
Asian countries in terms of non-communicable/communicable diseases. The QALY 
was the preferred measure for non-communicable diseases in China and Thailand. 
While the DALY is used equally in communicable and non-communicable diseases 
in China, it is used predominantly for non-communicable diseases in Thailand. 
This presents a challenge to health care managers; while it is clear that QALY is 
used mostly for non-communicable diseases, the most appropriate use of the 
DALY is unclear. Further research into the characteristics of diseases within these 
categories is required.
